A weekly summary of Novamind news and media
Dr. Steve Thayer with an important reminder that, for some, the holidays can be a difficult time of year for many reasons. He shares tips to care for our mental health and wellbeing over the holidays.
We are pleased to announce the signing of a definitive agreement to acquire Arizona-based Foundations for Change, a mental health practice specialized in ketamine-assisted psychotherapy, from its sole stockholder, Jeff Edelman. The transaction is subject to regulatory approvals and is expected to close in January 2022.
Opened in 2017 by Jeff Edelman, Foundations currently operates one outpatient mental health clinic in Peoria, Arizona with an annual revenue run rate in excess of US$800,000 and owns a second, larger location in Phoenix that is scheduled to open in early 2022. Foundations will temporarily operate as “Foundations for Change by Novamind” until the Company completes its recently announced rebrand. Mr. Edelman will continue in a leadership capacity as Medical Director for both clinics. Mr. Edelman is double board-certified Family Psychiatric-Mental Health Nurse Practitioner and a Child and Adolescent Psychiatric-Mental Health Clinical Nurse Specialist. As a former military combat veteran, who served in the US Army 55th Medical Co. Combat Stress Control unit, Mr. Edelman has special expertise in treating military veterans and first responders who struggle with stress and trauma.
Read the full release here.
December 23, 2021
December 21, 2021
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison catch up after their recent trip to the “Horizons: Perspectives on Psychedelics” conference in New York. Stay tuned next week for our last episode of 2021 and a special PTF podcast contest and giveaway.
Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com.
Email us questions and feedback at firstname.lastname@example.org.
NBC News reports on a first-of-its kind clinical trial at the University of Washington School of Medicine to treat 30 medical professionals experiencing depression with a dose of synthetic psilocybin combined with psychotherapy. Some say that even five years ago, this would have been considered taboo. “That medical researchers are turning toward psilocybin to treat colleagues is representative of a growing curiosity and acceptance of the drug among those in the medical establishment.” We’re seeing that openness, too, through our Frontline KAP clinical pilot to help healthcare workers heal.
Lucid News covers how research partnerships exploring psychedelic-assisted psychotherapy as treatment option for veterans are gaining traction.
For further information, email us:
This content was originally published here.